Phathom Pharmaceuticals, Inc.
PHAT
$4.41
$0.194.50%
| Weiss Ratings | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.44 | |||
| Price History | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -27.47% | |||
| 30-Day Total Return | -30.44% | |||
| 60-Day Total Return | -44.11% | |||
| 90-Day Total Return | -74.29% | |||
| Year to Date Total Return | -39.84% | |||
| 1-Year Total Return | -43.24% | |||
| 2-Year Total Return | -38.06% | |||
| 3-Year Total Return | -63.94% | |||
| 5-Year Total Return | -82.51% | |||
| 52-Week High % Change | -78.59% | |||
| 52-Week Low % Change | 0.84% | |||
| Price | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $19.71 | |||
| 52-Week Low Price | $4.19 | |||
| 52-Week Low Price (Date) | Mar 13, 2025 | |||
| 52-Week High Price (Date) | Sep 19, 2024 | |||
| Valuation | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 288.55M | |||
| Enterprise Value | 546.24M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.35 | |||
| Earnings Per Share Growth | 37.69% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.43 | |||
| Price/Book (Q) | -1.14 | |||
| Enterprise Value/Revenue (TTM) | 9.89 | |||
| Price | $4.41 | |||
| Enterprise Value/EBITDA (TTM) | -1.97 | |||
| Enterprise Value/EBIT | -1.97 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 71.04M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 877 742 8466 | |||
| Address | 100 Campus Drive Florham Park, NJ 07932 | |||
| Website | www.phathompharma.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -502.18% | |||
| Profit Margin | -605.09% | |||
| Management Effectiveness | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -43.78% | |||
| Return on Equity | -- | |||
| Income Statement | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 55.25M | |||
| Total Revenue (TTM) | 55.25M | |||
| Revenue Per Share | $0.78 | |||
| Gross Profit (TTM) | 47.28M | |||
| EBITDA (TTM) | -276.67M | |||
| EBIT (TTM) | -277.47M | |||
| Net Income (TTM) | -334.33M | |||
| Net Income Avl. to Common (TTM) | -334.33M | |||
| Total Revenue Growth (Q YOY) | 4,249.56% | |||
| Earnings Growth (Q YOY) | 6.43% | |||
| EPS Diluted (TTM) | -5.35 | |||
| EPS Diluted Growth (Q YOY) | 24.55% | |||
| Balance Sheet | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 297.26M | |||
| Cash Per Share (Q) | $4.18 | |||
| Total Current Assets (Q) | 360.13M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -253.58M | |||
| Current Ratio (Q) | 4.201 | |||
| Book Value Per Share (Q) | -$3.70 | |||
| Total Assets (Q) | 378.32M | |||
| Total Current Liabilities (Q) | 85.73M | |||
| Total Debt (Q) | 554.95M | |||
| Total Liabilities (Q) | 631.90M | |||
| Total Common Equity (Q) | -253.58M | |||
| Cash Flow | PHAT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -135.00K | |||
| Cash from Financing (TTM) | 182.77M | |||
| Net Change in Cash (TTM) | -84.13M | |||
| Levered Free Cash Flow (TTM) | -203.85M | |||
| Cash from Operations (TTM) | -266.77M | |||
